On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effect.MediPharm Labs has already supplied product for over 10 active clinical trials, including a U.S. National Institutes of Health funded study, and has completed multiple API and clinical trial material shipments to the United States.MediPharm Labs is ready today to support expanded U.S. clinical research and pharmaceutical development through its GMP US FDA site registration and Health Canada Drug Establishment License ('DEL”). TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm”, 'MediPharm Labs” or the 'Company”) a pharmaceutical company specialized in precision-based cannabinoids, welcomes the implementation of the U.S. final order rescheduling certain cannabis products from Schedule I to Schedule III of the Controlled Substances Act (the 'Order”). The Order took effect April 22, 2026. It recognizes the medical use of cannabis and is anticipated to materially reduce barriers to U.S. clinical research and pharmaceutical development.
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
